February 05, 2019
Celgene Corp. and Bristol-Myers Squibb Co. were hit with a proposed class action on Monday, as a Celgene investor claimed in Delaware federal court that not enough information has been provided about the companies' proposed $74 billion merger for stockholders to make an informed vote on the transaction.